Replimune Group (NASDAQ:REPL) Price Target Raised to $22.00

Replimune Group (NASDAQ:REPL) had its price objective boosted by research analysts at HC Wainwright from $21.00 to $22.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 59.54% from the company’s previous close.

REPL has been the topic of a number of other research reports. Jefferies Financial Group increased their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. BMO Capital Markets increased their price target on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Replimune Group has a consensus rating of “Buy” and a consensus target price of $19.29.

Replimune Group Stock Performance

Shares of Replimune Group stock opened at $13.79 on Thursday. Replimune Group has a 12 month low of $4.92 and a 12 month high of $17.00. The firm has a market capitalization of $943.51 million, a P/E ratio of -4.52 and a beta of 1.30. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The business has a fifty day simple moving average of $12.49 and a two-hundred day simple moving average of $11.67.

Replimune Group (NASDAQ:REPL) last released its earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, equities analysts forecast that Replimune Group will post -2.88 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the sale, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in REPL. China Universal Asset Management Co. Ltd. grew its holdings in Replimune Group by 24.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company’s stock valued at $198,000 after buying an additional 3,177 shares in the last quarter. SG Americas Securities LLC increased its holdings in Replimune Group by 14.7% in the 4th quarter. SG Americas Securities LLC now owns 26,291 shares of the company’s stock valued at $318,000 after acquiring an additional 3,374 shares during the last quarter. Creative Planning grew its position in shares of Replimune Group by 28.7% during the third quarter. Creative Planning now owns 21,047 shares of the company’s stock valued at $231,000 after purchasing an additional 4,699 shares in the last quarter. MetLife Investment Management LLC increased its holdings in shares of Replimune Group by 21.5% in the third quarter. MetLife Investment Management LLC now owns 35,134 shares of the company’s stock worth $385,000 after purchasing an additional 6,216 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its position in shares of Replimune Group by 81.7% in the third quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock worth $165,000 after buying an additional 6,748 shares in the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.